{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:29:14Z","timestamp":1786408154020,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2025307007"],"award-info":[{"award-number":["H2025307007"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04986-0","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:56:39Z","timestamp":1780678599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual GIP\/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2\/CCR2 axis"],"prefix":"10.1186","volume":"26","author":[{"given":"Yongning","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanfan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"9","key":"4986_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10290","key":"4986_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324.","journal-title":"Lancet"},{"issue":"1","key":"4986_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025;11(1):14.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"4986_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4986_CR5","doi-asserted-by":"crossref","unstructured":"Chen Q, et al. Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD). Nutrients. 2017;9(2):96.","DOI":"10.3390\/nu9020096"},{"issue":"5","key":"4986_CR6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","volume":"68","author":"T Jensen","year":"2018","unstructured":"Jensen T, et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68(5):1063\u201375.","journal-title":"J Hepatol"},{"key":"4986_CR7","doi-asserted-by":"crossref","unstructured":"Vancells Lujan P, Vi\u00f1as E, Esmel, Sacanella Meseguer E. Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients. 2021;13(5):1442.","DOI":"10.3390\/nu13051442"},{"key":"4986_CR8","doi-asserted-by":"crossref","unstructured":"Recena Aydos L, et al. Nonalcoholic Fatty Liver Disease Induced by High-Fat Diet in C57bl\/6 Models. Nutrients. 2019;11(12):3067.","DOI":"10.3390\/nu11123067"},{"issue":"9","key":"4986_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691\u2013705.","journal-title":"Gut"},{"issue":"7","key":"4986_CR10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578\u201388.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"4986_CR11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","volume":"59","author":"EASL-EASD","year":"2016","unstructured":"EASL-EASD-. EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia, 2016. 59(6): pp. 1121\u201340.","journal-title":"Diabetologia"},{"issue":"9","key":"4986_CR12","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","volume":"179","author":"DA Koutoukidis","year":"2019","unstructured":"Koutoukidis DA, et al. Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. JAMA Intern Med. 2019;179(9):1262\u201371.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"4986_CR13","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537\u201364.","journal-title":"Cell"},{"key":"4986_CR14","doi-asserted-by":"crossref","unstructured":"Mehrabian M et al. Localization of monocyte chemotactic protein-1 gene (SCYA2) to human chromosome 17q11.2-q21.1. .Genomics. 1991;9(1):200\u2013203.","DOI":"10.1016\/0888-7543(91)90239-B"},{"issue":"1","key":"4986_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0165-5728(94)90220-8","volume":"50","author":"BP Barna","year":"1994","unstructured":"Barna BP, et al. Regulation of monocyte chemoattractant protein-1 expression in adult human non-neoplastic astrocytes is sensitive to tumor necrosis factor (TNF) or antibody to the 55-kDa TNF receptor. J Neuroimmunol. 1994;50(1):101\u20137.","journal-title":"J Neuroimmunol"},{"issue":"15","key":"4986_CR16","doi-asserted-by":"publisher","first-page":"9912","DOI":"10.1016\/S0021-9258(18)92905-4","volume":"266","author":"TJ Standiford","year":"1991","unstructured":"Standiford TJ, et al. Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells. J Biol Chem. 1991;266(15):9912\u20138.","journal-title":"J Biol Chem"},{"issue":"8","key":"4986_CR17","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.4049\/jimmunol.1400337","volume":"193","author":"RJ Lin","year":"2014","unstructured":"Lin RJ, et al. MCPIP1 suppresses hepatitis C virus replication and negatively regulates virus-induced proinflammatory cytokine responses. J Immunol. 2014;193(8):4159\u201368.","journal-title":"J Immunol"},{"issue":"12","key":"4986_CR18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s13238-020-00739-1","volume":"11","author":"R Xu","year":"2020","unstructured":"Xu R, et al. How are MCPIP1 and cytokines mutually regulated in cancer-related immunity? Protein Cell. 2020;11(12):881\u201393.","journal-title":"Protein Cell"},{"issue":"6","key":"4986_CR19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMra052723","volume":"354","author":"IF Charo","year":"2006","unstructured":"Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"4986_CR20","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hep.29544","volume":"67","author":"O Krenkel","year":"2018","unstructured":"Krenkel O, et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatol. 2018;67(4):1270\u201383.","journal-title":"Hepatol"},{"issue":"3","key":"4986_CR21","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jhep.2019.10.028","volume":"72","author":"A Hammoutene","year":"2020","unstructured":"Hammoutene A, et al. A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis. J Hepatol. 2020;72(3):528\u201338.","journal-title":"J Hepatol"},{"issue":"4","key":"4986_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","volume":"19","author":"R Hammoud","year":"2023","unstructured":"Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19(4):201\u201316.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"4986_CR23","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","volume":"30","author":"AE Adriaenssens","year":"2019","unstructured":"Adriaenssens AE, et al. Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake. Cell Metab. 2019;30(5):987\u2013e996986.","journal-title":"Cell Metab"},{"issue":"4","key":"4986_CR24","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","volume":"33","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 2021;33(4):833\u2013e844835.","journal-title":"Cell Metab"},{"issue":"24","key":"4986_CR25","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber D, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387(24):2245\u201357.","journal-title":"N Engl J Med"},{"issue":"12","key":"4986_CR26","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324.","journal-title":"N Engl J Med"},{"issue":"6","key":"4986_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, et al. Semaglutide 2\u00b74\u00a0mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511\u201322.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"4986_CR28","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.2337\/db24-0861","volume":"74","author":"D Shantaram","year":"2025","unstructured":"Shantaram D, et al. The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent Mechanism. Diabetes. 2025;74(9):1512\u201324.","journal-title":"Diabetes"},{"issue":"8","key":"4986_CR29","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","volume":"65","author":"T Karagiannis","year":"2022","unstructured":"Karagiannis T, et al. Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251\u201361.","journal-title":"Diabetologia"},{"issue":"1","key":"4986_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12944-024-02416-2","volume":"24","author":"J Liang","year":"2025","unstructured":"Liang J, et al. Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics. Lipids Health Dis. 2025;24(1):8.","journal-title":"Lipids Health Dis"},{"issue":"4","key":"4986_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299\u2013310.","journal-title":"N Engl J Med"},{"issue":"8","key":"4986_CR32","doi-asserted-by":"publisher","first-page":"101472","DOI":"10.1016\/j.jhepr.2025.101472","volume":"7","author":"ML Hartman","year":"2025","unstructured":"Hartman ML, et al. Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide. JHEP Rep. 2025;7(8):101472.","journal-title":"JHEP Rep"},{"key":"4986_CR33","doi-asserted-by":"publisher","first-page":"1659233","DOI":"10.3389\/fnut.2025.1659233","volume":"12","author":"T Ma","year":"2025","unstructured":"Ma T, et al. Distinct effects of semaglutide and tirzepatide on metabolic and inflammatory gene expression in brown adipose tissue of mice fed a high-fat, high-fructose diet. Front Nutr. 2025;12:1659233.","journal-title":"Front Nutr"},{"key":"4986_CR34","doi-asserted-by":"publisher","first-page":"117630","DOI":"10.1016\/j.bmc.2024.117630","volume":"100","author":"Y Dong","year":"2024","unstructured":"Dong Y, et al. Design of a novel long-acting dual GLP-1\/GIP receptor agonist. Bioorg Med Chem. 2024;100:117630.","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"4986_CR35","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1002\/ar.25117","volume":"306","author":"L Wu","year":"2023","unstructured":"Wu L, et al. Pure total flavonoids from citrus improve nonalcoholic steatohepatitis liver inflammatory responses by regulating the CCL2\/CCR2-PI3K-Akt signal transduction pathway. Anat Rec (Hoboken). 2023;306(12):3169\u201377.","journal-title":"Anat Rec (Hoboken)"},{"key":"4986_CR36","doi-asserted-by":"crossref","unstructured":"Chyau CC, et al. Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL\/6 Mice Model via AMPK\/Sirt1\/SREBP-1c\/PPAR\u03b3 Pathway. Int J Mol Sci. 2020;21(1):360.","DOI":"10.3390\/ijms21010360"},{"issue":"2","key":"4986_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","volume":"49","author":"E Cobbina","year":"2017","unstructured":"Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49(2):197\u2013211.","journal-title":"Drug Metab Rev"},{"issue":"39","key":"4986_CR38","doi-asserted-by":"publisher","first-page":"41434","DOI":"10.18632\/oncotarget.5163","volume":"6","author":"S Ceccarelli","year":"2015","unstructured":"Ceccarelli S, et al. LPS-induced TNF-\u03b1 factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. Oncotarget. 2015;6(39):41434\u201352.","journal-title":"Oncotarget"},{"issue":"5","key":"4986_CR39","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha AR, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017;66(5):1037\u201346.","journal-title":"J Hepatol"},{"issue":"4","key":"4986_CR40","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1053\/j.gastro.2015.12.037","volume":"150","author":"P Hirsova","year":"2016","unstructured":"Hirsova P, et al. Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes. Gastroenterol. 2016;150(4):956\u201367.","journal-title":"Gastroenterol"},{"issue":"5","key":"4986_CR41","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/labinvest.2012.45","volume":"92","author":"LJ Dixon","year":"2012","unstructured":"Dixon LJ, et al. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest. 2012;92(5):713\u201323.","journal-title":"Lab Invest"},{"issue":"10","key":"4986_CR42","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1172\/JCI60777","volume":"122","author":"J Petrasek","year":"2012","unstructured":"Petrasek J, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest. 2012;122(10):3476\u201389.","journal-title":"J Clin Invest"},{"issue":"12","key":"4986_CR43","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/cr.2015.139","volume":"25","author":"WT He","year":"2015","unstructured":"He WT, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1\u03b2 secretion. Cell Res. 2015;25(12):1285\u201398.","journal-title":"Cell Res"},{"key":"4986_CR44","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.intimp.2018.12.028","volume":"67","author":"C Jia","year":"2019","unstructured":"Jia C, et al. Role of pyroptosis in cardiovascular diseases. Int Immunopharmacol. 2019;67:311\u20138.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"4986_CR45","doi-asserted-by":"publisher","first-page":"e0159217","DOI":"10.1371\/journal.pone.0159217","volume":"11","author":"RH McMahan","year":"2016","unstructured":"McMahan RH, et al. Free Fatty Acids Differentially Downregulate Chemokines in Liver Sinusoidal Endothelial Cells: Insights into Non-Alcoholic Fatty Liver Disease. PLoS One. 2016;11(7):e0159217.","journal-title":"PLoS One"},{"key":"4986_CR46","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3389\/fimmu.2020.01802","volume":"11","author":"X Pan","year":"2020","unstructured":"Pan X, et al. Chemokines in Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Front Immunol. 2020;11:1802.","journal-title":"Front Immunol"},{"key":"4986_CR47","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.lfs.2019.04.050","volume":"228","author":"E Zhu","year":"2019","unstructured":"Zhu E, et al. CC chemokine receptor 2 functions in osteoblastic transformation of valvular interstitial cells. Life Sci. 2019;228:72\u201384.","journal-title":"Life Sci"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04986-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04986-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:38:16Z","timestamp":1786405096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04986-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4986"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04986-0","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"29 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal study protocol was approved by the Ethics Committee of Hebei General Hospital (protocol code 2025DW002) on January 9, 2025.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"497"}}